In MLL-driven forms of AML such as MLL-AF9 models, it has been demonstrated that both ZEB1 and ZEB2 may be direct transcriptional targets of this fusion protein [17,18] and may be essential downstream genetic determinants of AML progression and disease severity. Here, ZEB2 is linked to acute myeloid leukemia.